/ Biomarker

Hye-Jung Kim, et al. BMB reports 2008

1. Biomarker
1) Tissue inhibitor of metalloproteinase type 1
Tissue inhibitor of metalloproteinase type 1 (TIMP-1) matrix metalloproteinases
(MMPs) .
TIMP-1 .
TIMP-1
.
, .
TIMP-1 .
TIMP-1 . (1,2)

2) Five- serum-marker panel (spondin-2, DcR3, Trail-R2, Reg IV,MIC 1)

diaDexus 4(spondin-2, tumor necrosis factor receptor superfamily member 6B
(DcR3), TRAIL receptor 2 (TRAIL-R2) and Reg IV) Mayo clinic
600 . 4
macrophage inhibitory cytokine 1 (MIC1)
. CEA
. 5
. (3)

Marshall et al. Int.J.Cancer 2010.

3) Nicotinamide N-methyltransferase and proteasome activator complex subunit 3

Roche Diagnostics GmbH 2 16
, nicotinamide N-methyltransferase (NNMT) proteasome
activator complex subunit 3 (PSME3)
.
PSME3 CEA , NNMT CEA
. PSME3 CEA .

4) Collapsin response mediator protein-2

Wu collapsin response mediator protein-2 (CRMP-2) 201 210
.
CRMP-2 CEA . CEA
CRMP-2 77% 95% .
CRMP-2 CEA . (4)

5) Six SELDI peaks corresponding to apolipoprotein C1,complement C3a-desArg, 1antitrypsin and transferring
Martine surface-enhanced laser desorption/ionization (SELDI) mass spectrometry
, 4 (apolipoprotein C1,complement
C3a-desArg, 1-antitrypsin and transferring) .
95% 91%
CEA . Habermann C3a-desArg
.
C3a-desArg 97% 96% .
(5,6)

6) -Defensins
2 SELDI-TOF -defensin-1,

-defensin-2, and -defensin-3 .

69% 100% .
. (7,8)

7) Macrophage migration inhibitory factor

macrophage migration inhibitory factor (MIF) 129
53 , MIF
.
CEA , MIF 47.3% CEA
. (9)

8) Macrophage-colony stimulating factor

macrophage-colony stimulating factor (M-CSF) granulocyte-colony
stimulating factor .
M-CSF CEA CA 199
. (10,11)

9) Prolactin
Prolactin .
prolactin 77% 98% . (12)

10) M2-pyruvate kinase

M2-pyruvate kinase glycolytic enzyme pyruvate kinase isoform
.
M2-pyruvate kinase
. 48-58%,
90-95% .
CEA .

11) Methylated septin-9 DNA

Septin 9 gene belongs GTPase promoter region hypermethylation
.
hypermethylation . Epigenomics AG
SEPT9, NGFR TMEEF2 methylation .
DNA , enzyme-based qPCR .
SEPT9 cut-off 0.011 ug/L (52%)
(95%) . Grutzmann plasma septin 9 methylation
. plasma septin 9 methylation 72%
, 90% .
PRESEPT 8000 ,
90%, 88.8% 86.8%
. (13)
12) Five gene markers in whole blood

Han RNA .
5 (B-cell scaffold protein with ankyrin repeats 1 (BANK1), B-cell novel protein 1
(BCNP1), cytidine deaminase (CDS), FERM domain containing 3 (MGC20553), membranespanning 4-domains, subfamily A, member 1 (MS4A1))
88-94%, 64-77% . (14)

S Tao et al. British Journal of Cancer 2012.

2. Biomarker
** Genes and epigenetic markers
,
.
,
. DNA K-ras, p53, and adenomatous polyposis coli
(APC) .
K-ras Ras family 40-50% .
aberrant crypt foci 13-95%
. p53 30-60%
.

. APC , DNA biomarker 1990
.
biomarker . p53,
KRAS, APC, BAT-26 DNA
52-91%, 15-82% 93-100% .
( 795$)
. (15-18)
5 DNA
, , .
CRC 79-96% 46-94%, 21-69%
. 82-96%
75-91%, 44-86% .

.

 DNA point specificity

3-5 90% FOBT(point
specificity 95%)
DNA .
DNA (point sensitivity 50%) program sensitivity

.
DNA


1. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for
colorectal-cancer screening. N Engl J Med 1996; 334: 1559.
2. Greenberg PD, Bertario L, Gnauck R et al. A prospective multicenter evaluation of new
fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 2000; 95:
13318
3. Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. Noninvasive testing for colorectal cancer:
a review. Am J Gastroenterol 2005; 100: 1393403.
4. Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H, Kloer HU. Tumor M2-pyruvate
kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer. Anticancer Res
2000; 20: 49658.
5. Schulze G. The tumor marker tumor M2-PK: an application in the diagnosis of
gastrointestinal cancer. Anticancer Res 2000; 20: 49614.
6. Ewald N, Toepler M, Akinci A, Kloer HU, Bretzel RG, Hardt PD. Pyruvate kinase M2
(tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current
published data. Z Gastroenterol 2005; 43: 13137.
7. Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic
biomarker fecal tumor M2-PK. World J Gastroenterol 2006; 12: 700711.
8. Haug U, Rothenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H. Tumour M2-PK
as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected
older adults vs colorectal cancer patients. Br J Cancer 2007; 96: 132934.
9. Haug U, Hundt S, Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate
kinase for detection of colorectal adenomas in a large screening study. Br J Cancer 2008; 99:
1335.
10. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of
colorectal cancer. Dis Colon Rectum 1994; 37: 2727.
11. Irvine T, Scott M, Clark CI. A small rise in CEA is sensitive for recurrence after surgery
for colorectal cancer. Colorectal Dis 2007; 9: 52731.
12. Korner H, Soreide K, Stokkeland PJ, Soreide JA. Systematic follow-up after curative
surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs,
and compliance. J Gastrointest Surg 2005; 9: 3208.
13. Grutzmann R, Molnar B, Pilarsky C et al. Sensitive detection of colorectal cancer in
peripheral blood by septin 9 DNA methylation assay. PLoS ONE 2008; 3: e3759.
14. Fernandes LC, Kim SB, Saad SS, Matos D. Value of carcinoembryonic antigen and
cytokeratins for the detection of recurrent disease following curative resection of colorectal
cancer. World J Gastroenterol 2006; 12: 38914.
15. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal
occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med
2004; 351: 270414.
16. Ahlquist DA, Skoletsky JE, Boynton KA et al. Colorectal cancer screening by detection of
altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;
119: 121927
17. Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP, Ross ME. Sensitivity and
specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal
neoplasia. Clin Colorectal Cancer 2003; 3: 4753.
18. Syngal S, Stoffel E, Chung D et al. Detection of stool DNA mutations before and after
treatment of colorectal neoplasia. Cancer 2006; 106: 27783.